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Abstract
Objective—To estimate the maternal and fetal risks of smallpox vaccination during pregnancy.
Data Sources—MEDLINE, Web of Science, EMBASE, Global Health, ClinicalTrials.gov, and 
CINHAL from inception to September 2014.
Methods of Study Selection—We included published articles containing primary data 
regarding smallpox vaccination during pregnancy that reported maternal or fetal outcomes 
(spontaneous abortion, congenital defect, stillbirth, preterm birth, or fetal vaccinia).
Tabulations, Integration, and Results—The primary search yielded 887 articles. After hand-
searching, 37 articles were included: 18 articles with fetal outcome data and 19 case reports of 
fetal vaccinia. Outcomes of smallpox vaccination in 12,201 pregnant women were included. 
Smallpox vaccination was not associated with an increased risk of spontaneous abortion (pooled 
relative risk [RR] 1.03, confidence interval [CI] 0.76–1.41), stillbirth (pooled RR 1.03, CI 0.75–
1.40), or preterm birth (pooled RR 0.84, CI 0.62–1.15). When vaccination in any trimester was 
considered, smallpox vaccination was not associated with an increased risk of congenital defects 
(pooled RR 1.25, CI 0.99–1.56); however, first-trimester exposure was associated with an 
increased risk of congenital defects (2.4% compared with 1.5%, pooled RR 1.34, CI 1.02–1.77). 
No cases of fetal vaccinia were reported in the studies examining fetal outcomes; 21 cases of fetal 
vaccinia were identified in the literature, of which three neonates survived.
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Conclusion—The overall risk associated with maternal smallpox vaccination appears low. No 
association between smallpox vaccination and spontaneous abortion, preterm birth, or stillbirth 
was identified. First-trimester vaccination was associated with a small increase in congenital 
defects, but the effect size was small and based on limited data. Fetal vaccinia appears to be a rare 
consequence of maternal smallpox vaccination but is associated with a high rate of fetal loss.
Although the eradication of smallpox is a modern public health triumph, there is ongoing 
concern that smallpox virus (variola) could be used as a bioterrorist weapon. Given that 
routine childhood smallpox vaccination was discontinued in 1971, reintroduction of 
smallpox into the human population could have devastating consequences. Smallpox 
epidemics are generally associated with case-fatality rates of 30% or higher among 
unvaccinated populations.1 In the event of a reintroduction, pregnant women are at increased 
risk of complications from smallpox disease, including a higher rate of hemorrhagic 
smallpox, with an overall case-fatality rate of 70% for unvaccinated pregnant women.2–4 As 
part of national preparedness efforts, the U.S. government has stockpiled smallpox vaccine 
with plans for use in persons exposed to or at high risk for exposure in the event of 
bioterrorism, including pregnant women.5 Although pregnant women are at increased risk of 
complications from smallpox disease, past recommendations have varied as to whether 
pregnant women should receive smallpox vaccine given the concern for fetal infection with 
vaccinia (the virus that is included in the smallpox vaccine) and reports of an increased risk 
of pregnancy loss and birth defects with vaccination.6–9 The recommendations of the 
Advisory Committee on Immunization Practices indicate that pregnant women should not be 
vaccinated in a preevent setting.10 However, new clinical guidance for smallpox vaccine use 
in a postevent setting recommends that pregnant women who are exposed to smallpox or at 
high risk for smallpox infection should be vaccinated.5 To better understand the risks of 
smallpox vaccination in pregnancy, we conducted a systematic review to address the 
following questions: 1) What are the risks of adverse maternal outcomes associated with 
smallpox vaccination in pregnancy? 2) What are the risks of fetal complications 
(spontaneous abortion, congenital defects, stillbirth, and preterm birth) associated with 
smallpox vaccination in pregnancy? 3) What is the risk of fetal vaccinia associated with 
smallpox vaccination in pregnancy?
Sources
Two authors (M.L.B. and D.M.-D.) in conjunction with an expert Centers for Disease 
Control and Prevention librarian trained in systematic reviews conducted a search of the 
existing literature. We searched the following databases: MEDLINE, Web of Science, 
EMBASE, Global Health, ClinicalTrials.gov, and CINHAL from inception to September 
2014 to identify all listed publications in the medical literature discussing smallpox vaccine 
in pregnant women. We searched the databases using standard term indices to cover the 
concepts “smallpox,” “vaccination,” “pregnant,” “birth defect,” “preterm birth,” 
“miscarriage,” “maternal health,” and “fetal vaccinia.” We placed no restrictions on the 
language of publications for this review. After removal of duplicates, two authors (M.L.B. 
and D.M.-D.) screened the remaining publications for relevance and fulfillment of 
predefined inclusion and exclusion criteria discrepancies were adjudicated by a third 
reviewer (D.J.J.). In addition, we hand-searched the bibliographies of all selected articles to 
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identify additional references and communicated with the one of the authors of the most 
recent smallpox vaccine studies.11,12
Study Selection
In accordance with Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
guidelines,13 we conducted a systematic review of the maternal and fetal risks associated 
with smallpox vaccination during pregnancy. Inclusion criteria for articles were that they 
must: 1) contain primary data regarding pregnant women who received smallpox 
vaccination, 2) describe vaccine exposures that occurred at or beyond 2 weeks of gestation, 
and 3) include a report of maternal or fetal (spontaneous abortion, congenital defect, 
stillbirth, or preterm birth) outcomes. Unpublished reports, abstracts, policy guidelines, and 
review articles were excluded; however, bibliographies of these articles were used to 
identify additional primary references. Given the limited data, no restrictions were placed on 
the vaccinia virus strain contained in the vaccine, the time period of vaccination, or the 
country of origin of the report. Non-English articles were professionally translated.
Two reviewers (M.L.B., D.M.-D.) screened all the titles and relevant abstracts and selected 
articles for full-text review. Abstracts that indicated a primary data source for cases of 
smallpox vaccination during pregnancy prompted a full-text review of the article. Relevant 
non-English articles identified by title, abstract, or preliminary translation were evaluated by 
electronic translation (Google) and if applicable were professionally translated by a medical 
translationist.
Data elements extracted from the articles included: 1) geographic location, 2) gestational age 
at time of vaccination, 3) maternal outcomes, and 4) fetal outcomes. The two primary 
outcomes were spontaneous abortion (defined as pregnancy loss at less than 20 weeks of 
gestation) and major structural congenital defects (defined as a defect present at birth that 
has a serious, adverse effect on the neonate's health, development, or functional ability, as 
described by the Metropolitan Atlanta Congenital Defects Program).14 Primary outcomes 
were chosen based on previous studies that reported an increased risk of spontaneous 
abortion, congenital defects, or both.6–8 Secondary outcomes were stillbirth (defined as fetal 
death at 20 weeks of gestation or greater) and preterm delivery (defined as delivery at less 
than 37 completed weeks of gestation). In addition, cases of fetal vaccinia were identified 
and summarized.
Meta-analysis was performed using STATA 11 with the METAN and METAPROP 
software routines. Pooling of data was considered if there were at least two studies available 
for a particular outcome. In studies reporting a comparator (no vaccination), categorical data 
from relevant studies were used to calculate relative risks (RRs) with 95% confidence 
intervals (CIs). To avoid Simpson's15 paradox, which occurs when the total numerator is 
simple divided by the total denominator, we estimated the absolute risks by pooling the 
proportions form the individual studies using a random-effects model. For studies without a 
comparator, we performed meta-analysis of proportions and their exact binomial CIs using 
random-effects models. A correction factor of 0.001 was used when data from a study 
included a value of zero to permit calculation of proportions and 95% CIs. We combined 
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data using DerSimonian-Laird random-effects model even when there was no evidence of 
statistical heterogeneity.16 This more conservative random-effects model was chosen given 
the possibility of clinical heterogeneity between studies, regardless of statistical 
heterogeneity. This approach also provides more conservative estimates of effect size. 
Heterogeneity between studies was tested using Cochran's Q and Higgins I2 tests.17 We 
conservatively considered heterogeneity as significant for P <.1 or I2 greater than 30% in 
recognition of the modest statistical power of these tests for heterogeneity. Publication bias 
was assessed for the primary outcomes using funnel plots and formally tested using 
Harbord's test.18 Analyses were stratified by timing of vaccination (first trimester or any 
trimester) when studies reported that information.
We calculated the rate of spontaneous abortions as the number of documented spontaneous 
abortions divided by the total number of pregnant women with known final outcome (live 
birth, spontaneous abortion, or stillbirth) in the study. The rates of preterm birth or 
congenital defects were calculated using total number of live births reported in each study as 
the denominator. For congenital defects, if we were unable to classify a defect as major or 
minor, either because no description was provided or because the description was 
insufficient, we opted to be more inclusive and counted these as major defects. Given that 
most congenital defects originate in the first trimester of pregnancy (during embryogenesis), 
we performed an analysis examining the risk of congenital defects after first-trimester 
exposure. We also included an analysis of exposure during any trimester because some 
congenital defects can occur later in pregnancy and a number of studies included in our 
analysis did not specify trimester of exposure.
Results
The flow diagram of study identification for the systematic review is illustrated in Figure 1. 
Our search identified a total of 887 nonduplicate articles. A total of 865 English language 
articles were identified, of which 17 met our inclusion criteria. Reviewing references 
identified 11 additional English articles for inclusion. A total of 31 non-English articles were 
professionally translated based on the initial review of the English or translated abstract or 
from hand-searching, of which nine met inclusion criteria. Overall, 37 articles reported 
primary data; 18 articles described fetal outcomes in 12,201 pregnant women vaccinated 
against smallpox (Table 1); none of these included any cases of fetal vaccinia. The other 19 
articles describe cases of fetal vaccinia (Table 2). Adverse maternal outcomes were not 
specifically evaluated in any of the identified articles. No cases of maternal morbidity or 
mortality with smallpox vaccination were reported. Additionally, maternal morbidity or 
mortality was also not reported in any of the comparison groups. The results summary for 
the two primary outcomes, spontaneous abortion and congenital defect, and the secondary 
outcomes, stillbirth and preterm birth, is displayed in Table 3.
Thirteen of the included studies reported data on spontaneous abortion, a primary outcome 
of this review.6–8,11,19–27 Figure 2 shows the effect of smallpox vaccination on spontaneous 
abortion in studies with a comparison group including a subanalysis of first-trimester 
exposure. Overall, smallpox vaccination was not associated with a significantly increased 
risk of spontaneous abortion (pooled RR 1.03, 95% CI 0.76–1.41) (Table 3). When the three 
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studies restricted to first-trimester exposure were analyzed, there was also no significantly 
increased risk of spontaneous abortion (pooled RR 1.62, 95% CI 0.43–6.19). The rate of 
spontaneous abortion after smallpox vaccination at any time during pregnancy ranged from 
0% to 24.1% and after first-trimester vaccination, it ranged from 0% to 29.4%. This was 
comparable with the range of 1–22.2% in unexposed pregnant women. There was significant 
statistical heterogeneity between studies (I2=78.6%, P≤.001). The funnel plot and the 
Harbord test suggest no evidence of publication bias for this outcome (Harbord P=.99; Fig. 
2). Additionally, the proportional meta-analysis of five studies without a comparison group 
found an overall rate of spontaneous abortion in all trimesters of 4% (95% CI 1–8%) and of 
three studies with first-trimester exposure, the rate of spontaneous abortion was found to be 
14% (95% CI 3–26%).6,11,25–27
Fifteen studies reported data on congenital defects with smallpox vaccination, another 
primary outcome of this review.6,8,11,12,20–26,28–31 Figure 3 shows the effect of smallpox 
vaccination on congenital defects in studies with a comparison group including a 
subanalysis of first-trimester exposure. Overall, smallpox vaccination was not associated 
with a significantly increased risk of congenital defects (pooled RR 1.25, 95% CI 0.99–1.56) 
(Table 3). When the five studies restricted to first-trimester smallpox vaccine exposure were 
analyzed, an association with congenital defects was seen (2.4% compared with 1.5%, 
pooled RR 1.34, 95% CI 1.02–1.77).8,12,21,22,29 Overall, the rate of congenital defects 
ranged from 0.0% to 4.5% among women vaccinated at any time during pregnancy, 0.6–
4.5% among women vaccinated in the first trimester, and 0.8–3.7% among unexposed 
women. In the one study in which first-trimester vaccination was associated with a 
statistically increased risk of congenital defects (RR 2.60, 95% CI 1.07–6.32), three of the 
six neonates with congenital defects had clubfoot.8 No specific pattern of multiple defects 
was observed with smallpox vaccination. The other four studies evaluating first-trimester 
exposure to smallpox vaccination in pregnancy were not associated with a statistically 
increased risk of congenital defects.12,21,22,29 No statistical heterogeneity was noted 
between studies (I2=0.0%, P=.9). The funnel plot and the Harbord test suggest publication 
bias for this outcome (Harbord P=.045; Fig. 3). Additionally, the proportional meta-analysis 
of seven studies without a comparison group found a 1% (95% CI 0–1%) overall rate of 
congenital defects for exposure in all trimesters of pregnancy. For the four studies with first-
trimester exposure, the pooled rate of congenital defects was 0% (95% CI 0.0–
0.0%).6,11,20,25,26,30,31
Eleven studies reported data on stillbirth as an outcome.6,8,19,21–24,26,28,30,31 Among eight 
studies that included a comparison group, there was no significantly increased risk of 
stillbirth with smallpox vaccination (pooled RR 1.03, 95% CI 0.75–1.40) (Table 3). 
Stillbirth rates ranged from 1.5% to 4.2% among women vaccinated at any time during 
pregnancy, 0.9–14.7% among those vaccinated in the first trimester, and 1.2–3.9% among 
the unexposed cohort. The three largest studies, which each included greater than 1,000 
vaccinated pregnant women, found a stillbirth incidence of 1.5%, 1.9%, and 4.2%, none of 
which were significantly different than the rate among unexposed women of 0.9%, 1.5%, 
and 3.9%, respectively.8,19,28 The proportional meta-analysis of four studies without a 
comparison group found an overall rate of stillbirth of 4% (95% CI 2–6%).6,26,30,31
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Eleven studies included data on preterm birth.6,8,11,12,19–21,25,29–31 Among six studies that 
included a comparison group, no increased risk of preterm birth with smallpox vaccination 
(pooled RR 0.84, 95% CI 0.62–1.15) was observed (Table 3). The preterm birth rate among 
women vaccinated at any time during pregnancy in these studies ranged from 0.0% to 11.1% 
compared with an average rate of 7.0–38.8% in unvaccinated women. The proportional 
meta-analysis of five studies without a comparison group found an overall rate of preterm 
birth of 3% (95% CI 1–5%).6,11,25,30,31
Twenty-one cases of reported fetal vaccinia were identified from 19 articles (Table 2). The 
cases were reported from 1809 to 1985; the United Kingdom had the most reported cases 
(n=10)32–40 and three cases were from the United States.9,41,42 In these reported cases of 
fetal vaccinia, the stage of pregnancy at which the mother was vaccinated ranged from 3 
weeks to 8 months. The interval between vaccination and delivery and pregnancy loss was 4 
weeks to 24 weeks of gestation. Fetal vaccinia was associated with a high rate of fetal or 
neonatal loss; among the 21 reported cases, only three neonates survived.9,34,39 There were 
two cases of spontaneous abortion, one elective termination of pregnancy, seven stillbirths, 
and eight live births followed by death immediately or within 8 days of life (including one 
twin gestation at 22 weeks of gestation, of which both died).9,32–49 In 9 of the 18 cases of 
fetal and neonatal loss, vaccinia virus was isolated from fetal tissue or 
placenta.32,33,37,38,40,43,44,46,49 In the three cases in which neonates with reported fetal 
vaccinia survived, vaccinia virus was not reported to have been isolated.9,34,39 Fetal and 
neonatal losses from fetal vaccinia occurred after vaccination in all three trimesters.
Discussion
Smallpox vaccination among pregnant women was not associated with an increased risk of 
spontaneous abortion, preterm birth, or stillbirth, but first-trimester smallpox vaccination 
was associated with a small increase in the risk of congenital defects. No cases of fetal 
vaccinia were described in the 12,201 vaccinated pregnant women, and only 21 case reports 
of fetal vaccinia were identified in the literature. Risk of adverse maternal outcomes with 
smallpox vaccination could not be evaluated from these data.
Although we found an association between first-trimester exposure and congenital defects, 
the effect size was small and based on five studies. The pooled RR for congenital defects 
with first-trimester vaccination was 1.34. When compared with a background risk of 
congenital defects of approximately 3%, the absolute risk increase is approximately 1% for 
congenital defects among vaccinated women.50 On review of specific defects, one study 
reported an increased risk of clubfoot; however, this was an isolated finding.8 Clubfoot is a 
structural defect involving malposition of the foot and ankle, believed to occur early in 
pregnancy. Its pathogenesis is not well understood, but vascular disruption, neurologic 
disorder, and abnormal connective tissue development have all been proposed as possible 
mechanisms.51,52 In the largest study to date, Ryan et al12 found no increased risk of 
congenital defects, including clubfoot. Additionally, we found evidence of publication bias, 
which may exaggerate the association between first-trimester vaccination and smallpox 
vaccination. With the exception of the study by Ryan et al, the papers included in this 
analysis were published before 1976 and limited data were available on ascertainment of the 
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defects. Furthermore, in the meta-analysis of proportions, the risk of congenital defects with 
first-trimester exposure in studies without a comparison group was essentially null (0.0 
[95% CI 0.0–0.0]).
Two studies identified did not meet inclusion criteria because they focused on specific birth 
outcomes. In one study, smallpox vaccination was not associated with ocular 
abnormalities.53 In the second study, a wide range of neurologic abnormalities including 
seizures and poor movement were demonstrated more frequently in the vaccinated group.54 
No other study reported an association between vaccination and neurologic abnormalities.
Our meta-analysis found that smallpox vaccination during pregnancy was not associated 
with an increased risk of spontaneous abortion. MacArthur et al6 first examined this 
question, reporting a 29.4% risk of miscarriage with first-trimester vaccination. Estimating 
rates of spontaneous abortions is challenging. Spontaneous abortion is common with a 
baseline risk of approximately 12–15%.55 The range of spontaneous abortion we report is 
1.1–29.4%, a broad estimate that lacks precision.
Our meta-analysis also found no association between smallpox vaccination and 
stillbirth.8,19,21–24,28 Although MacArthur et al demonstrated an increased rate of stillbirth 
in association with first-trimester vaccination exposure (14.7%), the small sample size 
(n=34) and lack of a control group limit applicability of these findings.6 Additionally, this 
meta-analysis found no association between smallpox vaccination and preterm birth. 
Preterm birth is multifactorial with a number of known risk factors none of which were 
controlled for in these studies.56
Although smallpox vaccination appears to pose a risk of fetal vaccinia, the risk can be 
presumed to be very low based on the small number of cases identified (n=21) from our 
search spanning 1,809 to the present. Fetal vaccinia appears to be associated with a high rate 
of pregnancy loss. The diagnosis of fetal vaccinia in many reports was presumptive based on 
fetal and neonatal features. However, vaccinia virus was isolated from the fetus or placenta 
in some cases, demonstrating that transplacental transmission can occur.
This systematic review provides a comprehensive summary of the literature regarding 
smallpox vaccination in pregnancy. A strength of this review was our extensive search of the 
literature, including non-English articles. Given that smallpox is now eradicated and 
additional data are unlikely to become available, this review is useful to guide clinical 
recommendations regarding smallpox vaccine use in pregnancy during an emergency 
bioterrorist response. Our study also has several limitations. There is paucity of evidence 
regarding safety of smallpox vaccination in pregnancy and the available evidence is 
generally of poor quality. No randomized clinical trial data were available. Additionally, the 
studies differed in timeframe, geographic location, smallpox vaccine used, study designs, 
and outcomes evaluated.
In conclusion, we did not find an association between spontaneous abortion, preterm birth, 
or stillbirth and smallpox vaccination; however, first-trimester smallpox vaccination was 
associated with a small increase in congenital defects. The effect size observed was small 
and no specific pattern of defects was observed. These findings must be viewed in the 
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context of the high morbidity and mortality of smallpox disease in pregnancy, both for the 
mother and fetus. Fetal vaccinia appears to be an extremely rare consequence of maternal 
smallpox vaccination. Despite the limits of these data, the overall risk of using smallpox 
vaccine during pregnancy appears low and supports the recent Centers for Disease Control 
and Prevention recommendation that pregnant women exposed to smallpox or at high risk 
for smallpox infection should be vaccinated.5
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Fig. 1. 
Flow diagram of studies included in systematic review and meta-analysis of smallpox 
vaccination in pregnancy.
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Fig. 2. 
Forest plots showing the effect of smallpox vaccination on risk of spontaneous abortion in 
all trimesters (A) and in the first trimester (B). Funnel plot with pseudo 95% confidence 
limits showing the effect of smallpox vaccination on spontaneous abortion (C). RR, risk 
ratio; CI, confidence interval.
Badell et al. Page 12
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 3. 
Forest plots showing the effect of smallpox vaccination on risk of congenital defects in all 
trimesters (A) and in the first trimester (B). Funnel plot with pseudo 95% confidence limits 
showing the effect of smallpox vaccination on risk of congenital defects (C). RR, risk ratio; 
CI, confidence interval.
Badell et al. Page 13
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Badell et al. Page 14
Ta
bl
e 
1
C
ha
ra
ct
er
ist
ic
s o
f I
nc
lu
de
d 
St
ud
ie
s W
ith
 a
nd
 W
ith
ou
t a
 C
om
pa
ri
so
n 
G
ro
up
 E
va
lu
at
in
g 
R
isk
 o
f S
po
nt
an
eo
us
 A
bo
rt
io
n,
 C
on
ge
ni
ta
l D
ef
ec
ts
, 
St
ill
bi
rt
h,
 o
r P
re
te
rm
 B
ir
th
 W
ith
 S
m
al
lp
ox
 V
ac
ci
na
tio
n 
in
 P
re
gn
an
cy
St
ud
y
Y
ea
r
C
ou
nt
ry
St
ud
y 
D
es
ig
n
In
cl
us
io
n 
C
ri
te
ri
a
V
ac
ci
na
te
d 
in
 P
re
gn
an
cy
V
ac
ci
na
te
d 
in
 F
ir
st
 
Tr
im
es
te
r
U
ne
xp
os
ed
 (n
=3
3,4
87
)
Le
ve
l o
f E
vi
de
nc
e*
St
ud
ie
s I
nc
lu
di
ng
 a
 
Co
m
pa
ris
on
 G
ro
up
n
=
10
,8
25
n
=
6,
04
0
 
R
ya
n 
et
 a
l12
20
08
U
.S
.
R
et
ro
sp
ec
tiv
e 
co
ho
rt
M
ili
ta
ry
 w
om
en
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y
88
2
67
2
M
ili
ta
ry
 w
om
en
 w
ith
 n
o 
hi
sto
ry
 o
f s
m
al
lp
ox
 
v
ac
ci
na
tio
n,
 n
=2
3,
68
5
II
 
N
ad
er
i e
t a
l8
19
75
Ir
an
Pr
os
pe
ct
iv
e 
co
ho
rt
R
eg
ist
er
ed
 p
re
gn
an
t 
w
o
m
en
 v
ac
ci
na
te
d 
du
rin
g 
m
as
s v
ac
ci
na
tio
n 
pr
og
ra
m
1,
52
2
21
1
N
on
va
cc
in
at
ed
 p
re
gn
an
t 
w
o
m
en
 in
 sa
m
e 
in
sti
tu
tio
n 
du
rin
g 
th
e 
ye
ar
 a
fte
r m
as
s 
v
ac
ci
na
tio
n 
pr
og
ra
m
, 
n
=
2,
02
4
II
 
La
dn
yi
 e
t a
l19
19
74
R
us
sia
Pr
os
pe
ct
iv
e 
co
ho
rt
R
eg
ist
er
ed
 p
re
gn
an
t 
w
o
m
en
 v
ac
ci
na
te
d 
du
rin
g 
m
as
s v
ac
ci
na
tio
n 
pr
og
ra
m
1,
17
2
36
6
Pr
eg
na
nt
 w
om
en
 se
en
 
du
rin
g 
in
te
re
pi
de
m
ic
 p
er
io
d 
n
o
t v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y,
 n
=7
77
II
 
R
ajh
va
jn 
et 
al2
0
19
73
Cr
oa
tia
R
et
ro
sp
ec
tiv
e 
su
rv
ey
Pr
eg
na
nt
 w
om
en
 
co
n
ce
iv
ed
 b
ef
or
e 
m
as
s 
v
ac
ci
na
tio
n 
re
po
rti
ng
 
v
ac
ci
na
tio
n 
up
 to
 fo
ur
th
 
m
o
n
th
 o
f p
re
gn
an
cy
25
7
Pr
eg
na
nt
 w
om
en
 c
on
ce
iv
ed
 
be
fo
re
 m
as
s v
ac
ci
na
tio
n 
w
ho
 w
er
e 
no
t v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y,
 n
=2
66
II
 
Ja
ni
sz
ew
sk
i e
t a
l21
19
66
Po
la
nd
R
et
ro
sp
ec
tiv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y
20
5
19
3
Pr
eg
na
nt
 w
om
en
 d
ur
in
g 
th
e 
sa
m
e 
tim
e 
pe
rio
d 
w
ho
 w
er
e 
n
o
t v
ac
ci
na
te
d,
 n
=6
94
II
 
B
ou
rk
e 
et
 a
l22
19
64
Ir
el
an
d
Pr
os
pe
ct
iv
e 
co
ho
rt
R
eg
ist
er
ed
 p
re
gn
an
t 
w
o
m
en
 v
ac
ci
na
te
d 
du
rin
g 
sm
al
lp
ox
 
o
u
tb
re
ak
12
2
54
Pr
eg
na
nt
 w
om
en
 n
ot
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y 
se
en
 fo
r f
irs
t 
pr
en
at
al
 v
isi
t o
n 
sa
m
e 
da
y 
as
 e
x
po
se
d 
(fo
ur 
ad
jac
en
t 
ch
ar
ts)
, n
=4
48
II
 
Li
eb
es
ch
ue
tz
 e
t a
l23
19
64
En
gl
an
d
Pr
os
pe
ct
iv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 le
ss
 
th
an
 5
 m
o 
va
cc
in
at
ed
 
du
rin
g 
m
as
s v
ac
ci
na
tio
n 
pr
og
ra
m
15
7
12
6
Pr
eg
na
nt
 w
om
en
 n
ot
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y,
 n
=1
,6
57
II
 
A
br
am
ow
itz
 e
t a
l28
19
57
So
ut
h 
A
fri
ca
R
et
ro
sp
ec
tiv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 le
ss
 
th
an
 2
0 
w
k 
of
 g
es
ta
tio
n 
v
ac
ci
na
te
d 
du
rin
g 
sm
al
lp
ox
 o
ut
br
ea
k
1,
12
1
Pr
eg
na
nt
 w
om
en
 n
ot
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y,
 n
=2
01
II
 
B
ie
ni
ar
z 
et
 a
l7
19
56
Po
la
nd
R
et
ro
sp
ec
tiv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 
v
ac
ci
na
te
d 
du
rin
g 
m
as
s 
v
ac
ci
na
tio
n
49
5
Pr
eg
na
nt
 w
om
en
 n
ot
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y,
 n
=1
,3
76
II
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Badell et al. Page 15
St
ud
y
Y
ea
r
C
ou
nt
ry
St
ud
y 
D
es
ig
n
In
cl
us
io
n 
C
ri
te
ri
a
V
ac
ci
na
te
d 
in
 P
re
gn
an
cy
V
ac
ci
na
te
d 
in
 F
ir
st
 
Tr
im
es
te
r
U
ne
xp
os
ed
 (n
=3
3,4
87
)
Le
ve
l o
f E
vi
de
nc
e*
 
B
el
lo
w
s e
t a
l24
19
49
U
.S
.
Pr
os
pe
ct
iv
e 
co
ho
rt
R
eg
ist
er
ed
 p
re
gn
an
t 
w
o
m
en
 v
ac
ci
na
te
d 
du
rin
g 
m
as
s v
ac
ci
na
tio
n 
pr
og
ra
m
72
0
24
6
Pr
eg
na
nt
 w
om
en
 n
ot
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y,
 n
=1
73
II
 
G
re
en
be
rg
 e
t a
l29
19
49
U
.S
.
R
et
ro
sp
ec
tiv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 w
ith
 
v
ia
bl
e 
ne
on
at
e 
w
ho
 w
er
e 
v
ac
ci
na
te
d 
at
 le
ss
 th
an
 3
 
m
o
 d
ur
in
g 
m
as
s 
v
ac
ci
na
tio
n 
pr
og
ra
m
4,
17
2
4,
17
2
Pr
eg
na
nt
 w
om
en
 in
 sa
m
e 
cl
in
ic
 o
r h
os
pi
ta
l w
ho
 w
er
e 
n
o
t v
ac
ci
na
te
d,
 n
=2
,1
86
II
St
ud
ie
s W
ith
ou
t a
 
Co
m
pa
ris
on
 G
ro
up
n
=
1,
37
6
n
=
33
1
 
R
ya
n 
et
 a
l11
20
08
U
.S
.
Pr
os
pe
ct
iv
e 
re
gi
str
y
M
ili
ta
ry
 w
om
en
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y
20
8
20
3
N
A
II
 
To
pc
iu
 e
t a
l30
19
76
R
om
an
ia
Pr
os
pe
ct
iv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y
60
8 
(46
)†
7†
N
A
II
I
 
K
rs
ta
jic
 et
 al
25
19
73
Cr
oa
tia
Pr
os
pe
ct
iv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y
26
 (1
1)†
11
†
N
A
II
I
 
En
gs
tro
m
 e
t a
l26
19
66
Sw
ed
en
Pr
os
pe
ct
iv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 
(nu
rse
s, 
pro
fes
sio
na
ls,
 
ho
sp
ita
l p
at
ie
nt
s, 
th
os
e 
tr
av
el
in
g 
ab
ro
ad
) 
v
ac
ci
na
te
d 
du
rin
g 
pr
eg
na
nc
y
17
0
19
N
A
II
I
 
W
en
tw
or
th
 e
t a
l31
19
66
W
al
es
R
et
ro
sp
ec
tiv
e 
co
ho
rt
Pr
eg
na
nt
 w
om
en
 
v
ac
ci
na
te
d 
du
rin
g 
sm
al
lp
ox
 o
ut
br
ea
k 
at
 th
e 
tim
e 
a 
co
nt
in
uo
us
 se
rie
s 
o
f p
la
ce
nt
as
 w
er
e 
be
in
g 
co
lle
ct
ed
65
56
N
A
II
I
 
M
ac
A
rth
ur
 e
t a
l6
19
52
Sc
ot
la
nd
R
et
ro
sp
ec
tiv
e 
su
rv
ey
Pr
eg
na
nt
 w
om
en
 
re
po
rti
ng
 v
ac
ci
na
tio
n 
du
rin
g 
pr
eg
na
nc
y 
at
 ti
m
e 
o
f o
ut
br
ea
k
17
0
34
N
A
II
I
 
U
rn
er
 e
t a
l27
19
25
U
.S
.
Pr
os
pe
ct
iv
e 
co
ho
rt
R
eg
ist
er
ed
 p
re
gn
an
t 
w
o
m
en
 v
ac
ci
na
te
d 
du
rin
g 
sm
al
lp
ox
 
o
u
tb
re
ak
12
9
1
N
A
II
I
N
A
, n
ot
 a
pp
lic
ab
le
.
*
Le
ve
l o
f e
vi
de
nc
e:
 I,
 a
 ra
nd
om
iz
ed
, c
on
tro
lle
d 
tri
al
; I
I, 
a 
co
ho
rt 
or
 c
as
e-
co
nt
ro
lle
d 
stu
dy
 th
at
 in
cl
ud
es
 a
 c
om
pa
ris
on
 g
ro
up
; I
II,
 a
n 
un
co
nt
ro
lle
d 
de
sc
rip
tiv
e 
stu
dy
 in
cl
ud
in
g 
ca
se
 se
rie
s.
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Badell et al. Page 16
† E
xc
lu
de
s w
om
en
 w
ho
 u
nd
er
w
en
t a
bo
rti
on
 o
r h
ad
 a
n 
ea
rly
 p
re
gn
an
cy
 lo
ss
.
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Badell et al. Page 17
Ta
bl
e 
2
C
as
es
 o
f F
et
al
 V
ac
ci
ni
a 
Id
en
tif
ie
d 
in
 1
9 
A
rt
ic
le
s R
ep
or
tin
g 
a 
To
ta
l o
f 2
1 
C
as
es
A
ut
ho
r
Y
ea
r
C
ou
nt
ry
G
es
ta
tio
na
l 
A
ge
 a
t 
V
ac
ci
na
tio
n
G
es
ta
tio
na
l 
A
ge
 o
r 
W
ei
gh
t 
a
t D
el
iv
er
y
O
ut
co
m
e
Pa
th
ol
og
ic
 o
r 
C
lin
ic
al
 S
um
m
ar
y
V
ir
us
 Is
ol
at
ed
D
os
 S
an
to
s e
t a
l44
19
85
B
ra
zi
l
12
 w
k
20
 w
k
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
Sk
in
 w
ith
 la
rg
e 
nu
m
be
r o
f t
yp
ic
al
 v
ac
ci
ni
a 
le
sio
ns
Y
es
CD
C4
9
19
79
A
us
tra
lia
8 
w
k
24
 w
k
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
M
ul
tip
le
 sk
in
 le
sio
ns
 a
nd
 li
ve
r l
es
io
n
Y
es
H
ar
le
y 
an
d 
G
ill
es
pi
e3
4
19
72
En
gl
an
d
3–
4 
m
o
2,
80
0 
g
Li
ve
 b
irt
h:
 su
rv
iv
ed
“
V
er
y 
re
d”
 sc
ar
s o
n 
bo
dy
 a
t t
im
e 
of
 d
el
iv
er
y,
 
sc
ar
rin
g 
of
 e
ye
lid
, m
ac
ul
a 
de
str
uc
tio
n 
an
d 
hy
po
pl
as
tic
 b
on
e 
ch
an
ge
s
N
ot
 te
ste
d
A
itk
en
s e
t a
l43
19
68
A
us
tra
lia
15
 w
k
23
–2
4 
w
k
IU
FD
Sk
in
 w
ith
 n
um
er
ou
s r
in
g 
or
 ta
rg
et
-s
ha
pe
d 
le
sio
ns
, w
hi
te
 n
ec
ro
tic
 le
sio
ns
 in
 li
ve
r, 
he
ar
t, 
an
d 
lu
ng
s
Y
es
La
ne
9
19
70
U
.S
.
1–
2 
m
o
32
 w
k
Li
ve
 b
irt
h:
 su
rv
iv
ed
Po
ck
-li
ke
 sc
ar
rin
g 
en
tir
e 
bo
dy
, w
el
l 
de
ve
lo
pe
d 
no
rm
al
ly
N
ot
 st
at
ed
G
re
en
 e
t a
l—
ca
se
 1
33
19
66
Sc
ot
la
nd
24
 w
k
30
 w
k
IU
FD
Sk
in
 le
sio
ns
 c
on
ce
nt
ric
, t
ar
ge
t-l
ik
e,
 fo
ci
 o
f 
n
ec
ro
sis
 k
id
ne
y,
 li
ve
r, 
lu
ng
s
N
ot
 te
ste
d
G
re
en
 e
t a
l—
ca
se
 2
33
19
66
Sc
ot
la
nd
14
 w
k
18
 w
k
Sp
on
ta
ne
ou
s a
bo
rti
on
Sc
at
te
re
d 
ta
rg
et
-li
ke
 le
sio
ns
 o
n 
sk
in
, f
oc
i o
f 
n
ec
ro
sis
 in
 lu
ng
s a
nd
 li
ve
r
Y
es
En
tw
ist
le
 e
t a
l32
19
62
W
al
es
19
 w
k
25
 w
k
IU
FD
Sk
in
 w
ith
 la
rg
e,
 ra
ise
d,
 c
on
ge
ste
d 
u
m
bi
lic
at
ed
 le
sio
ns
, l
es
io
ns
 in
 k
id
ne
y,
 li
ve
r, 
an
d 
lu
ng
s
Y
es
K
ill
pa
ck
35
19
63
En
gl
an
d
12
 w
k
22
 w
k
IU
FD
N
um
er
ou
s h
em
or
rh
ag
ic
 sp
ot
s o
n 
sk
in
N
ot
 te
ste
d
Ly
ck
e 
et
 a
l46
19
63
Sw
ed
en
23
 w
k
28
 w
k
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
G
en
er
al
iz
ed
 sk
in
 le
sio
ns
 a
nd
 li
ve
r n
ec
ro
sis
Y
es
N
ai
do
o 
an
d 
H
irs
ch
37
19
63
Lo
nd
on
22
–2
4 
w
k
30
–3
2 
w
k
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
D
isc
re
te
 re
d 
ci
rc
ul
ar
 u
lc
er
s c
ov
er
in
g 
sk
in
, 
le
sio
ns
 in
 lu
ng
s, 
liv
er
, a
nd
 k
id
ne
ys
Y
es
To
en
du
ry
 a
nd
 F
ou
ka
s —
ca
se
 1
47
19
64
G
re
ec
e
4 
w
k
18
 w
k
IU
FD
Ty
pi
ca
l s
m
al
lp
ox
 e
xa
nt
he
m
 o
n 
bo
dy
N
ot
 te
ste
d
To
en
du
ry
 a
nd
 F
ou
ka
s—
ca
se
 2
47
19
64
G
re
ec
e
3 
w
k
12
 w
k
V
ol
un
ta
ry
 in
te
rru
pt
io
n 
of
 
pr
eg
na
nc
y
N
ec
ro
sis
 fo
ci
 in
 v
ill
i, 
su
be
pi
de
rm
al
 n
ec
ro
sis
N
ot
 te
ste
d
Tu
ck
er
 a
nd
 S
ib
so
n3
8
19
62
En
gl
an
d
2.
5 
m
o
22
 w
k
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
×2
D
isc
re
te
 v
ac
ci
ni
al
 le
sio
ns
 o
ve
r b
od
y
Y
es
W
ad
di
ng
to
n 
et
 a
l39
19
64
W
al
es
6 
m
o
32
 w
k
Li
ve
 b
irt
h:
 su
rv
iv
ed
W
id
es
pr
ea
d 
ve
sic
le
s r
es
em
bl
in
g 
pr
og
re
ss
iv
e 
v
ac
ci
ni
a
N
o
K
ro
ph
ol
le
r a
nd
 V
oo
rh
oe
ve
-D
en
 
H
ar
to
g4
5
19
62
H
ol
la
nd
15
 w
k
22
 w
k
IU
FD
G
en
er
al
iz
ed
 sk
in
 le
sio
ns
 w
hi
ch
 re
se
m
bl
ed
 
v
ac
ci
ni
a 
er
up
tio
ns
N
ot
 te
ste
d
H
oo
d4
1
19
63
U
.S
.
1.
5 
m
o
4.
5–
5 
m
o
Sp
on
ta
ne
ou
s a
bo
rti
on
N
um
er
ou
s c
irc
ul
ar
 le
sio
ns
 w
ith
 sl
ig
ht
ly
 
de
pr
es
se
d 
ce
nt
ra
l a
re
a,
 n
ec
ro
tic
 le
sio
ns
 o
f 
lu
ng
N
o
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Badell et al. Page 18
A
ut
ho
r
Y
ea
r
C
ou
nt
ry
G
es
ta
tio
na
l 
A
ge
 a
t 
V
ac
ci
na
tio
n
G
es
ta
tio
na
l 
A
ge
 o
r 
W
ei
gh
t 
a
t D
el
iv
er
y
O
ut
co
m
e
Pa
th
ol
og
ic
 o
r 
C
lin
ic
al
 S
um
m
ar
y
V
ir
us
 Is
ol
at
ed
W
ie
rs
um
48
19
55
N
et
he
rla
nd
s
6 
w
k 
be
fo
re
Pr
em
at
ur
e
IU
FD
N
um
er
ou
s s
po
ts 
on
 sk
in
 st
ro
ng
ly
 re
se
m
bl
in
g 
sm
al
lp
ox
 p
us
tu
le
s
N
ot
 te
ste
d
M
ac
D
on
al
d 
an
d 
M
ac
A
rth
ur
36
19
53
Sc
ot
la
nd
3 
m
o
6 
m
o
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
M
ul
tip
le
 d
isc
re
te
 c
irc
ul
ar
, u
m
bi
lic
at
ed
 sk
in
 
le
sio
ns
N
ot
 te
ste
d
Ly
nc
h4
2
19
32
U
.S
.
5 
m
o
6 
m
o
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
G
en
er
al
iz
ed
 e
ru
pt
io
ns
 c
on
sis
tin
g 
of
 ra
ise
d 
ci
rc
ul
ar
 p
la
qu
es
 w
ith
 c
en
tra
l d
ep
re
ss
io
n,
 
le
sio
ns
 o
n 
liv
er
N
ot
 te
ste
d
Je
nn
er
40
18
09
En
gl
an
d
8 
m
o
9 
m
o
Li
ve
 b
irt
h:
 n
eo
na
ta
l d
ea
th
M
an
y 
sk
in
 e
ru
pt
io
ns
, b
ea
rin
g 
m
uc
h 
th
e 
ap
pe
ar
an
ce
 o
f s
m
al
lp
ox
Y
es
CD
C,
 C
en
te
rs
 fo
r D
ise
as
e 
Co
nt
ro
l a
nd
 P
re
ve
nt
io
n;
 IU
FD
, i
nt
ra
ut
er
in
e 
fe
ta
l d
ea
th
.
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Badell et al. Page 19
Ta
bl
e 
3
R
es
ul
ts
 S
um
m
ar
y 
fo
r S
po
nt
an
eo
us
 A
bo
rt
io
n,
 C
on
ge
ni
ta
l D
ef
ec
ts
, S
til
lb
ir
th
, a
nd
 P
re
te
rm
 B
ir
th
 W
ith
 S
m
al
lp
ox
 V
ac
ci
na
tio
n 
in
 P
re
gn
an
cy
O
ut
co
m
e
N
o.
 o
f S
tu
di
es
C
on
tr
ol
 (n
/N
)
C
on
tr
ol
 (%
)*
V
ac
ci
na
te
d 
(n
/N
)
V
ac
ci
na
te
d 
(%
)*
M
ea
su
re
 o
f E
ffe
ct
*
Ef
fe
ct
 S
iz
e (
95
%
 C
I)
H
et
er
og
en
ei
ty
 (%
)
Pr
im
ar
y
 
Sp
on
ta
ne
ou
s a
bo
rti
on
 
 
Fi
rs
t t
rim
es
te
r
3
13
6/
3,
49
5
5.
5
44
/7
70
5.
7
Po
ol
ed
 R
R 
(ra
nd
om
)
1.
62
 (0
.43
–6
.19
)
I2
 
=
 9
2.
9
 
 
A
ll 
tri
m
es
te
rs
8
45
7/
7,
56
0
6.
7
24
6/
4,
64
0
7.
7
Po
ol
ed
 R
R 
(ra
nd
om
)
1.
03
 (0
.76
–1
.41
)
I2
=
62
.5
 
Co
ng
en
ita
l d
ef
ec
t
 
 
Fi
rs
t t
rim
es
te
r
5
91
7/
28
,8
79
1.
5
80
/5
,2
74
2.
4
Po
ol
ed
 R
R 
(ra
nd
om
)
1.
34
 (1
.02
–1
.77
)
I2
=
0.
0
 
 
A
ll 
tri
m
es
te
rs
8
94
6/
30
,8
04
1.
6
15
3/
8,
78
1
2.
1
Po
ol
ed
 R
R 
(ra
nd
om
)
1.
25
 (0
.99
–1
.56
)
I2
=
0.
0
Se
co
nd
ar
y
 
St
ill
bi
rth
 
 
A
ll 
tri
m
es
te
rs
7
12
1/
5,
97
4
2.
4
12
6/
5,
00
9
2.
4
Po
ol
ed
 R
R 
(ra
nd
om
)
1.
03
 (0
.75
–1
.4)
I2
=
10
.6
 
Pr
et
er
m
 b
irt
h
 
 
A
ll 
tri
m
es
te
rs
6
2,
20
5/
29
,3
70
10
.0
63
8/
7,
95
3
8.
0
Po
ol
ed
 R
R 
(ra
nd
om
)
0.
84
 (0
.62
–1
.15
)
I2
=
85
.6
CI
, c
on
fid
en
ce
 in
te
rv
al
; R
R,
 re
la
tiv
e 
ris
k.
*
Th
e 
pe
rc
en
ta
ge
s a
re
 p
oo
le
d 
fro
m
 th
e 
in
di
vi
du
al
 st
ud
ie
s u
sin
g 
ra
nd
om
-e
ffe
ct
s m
od
el
s.1
5
Obstet Gynecol. Author manuscript; available in PMC 2016 June 01.
